Home > Boards > US Listed > Medical - Equipment > Hancock Jaffe Laboratories, Inc. (HJLI)

Hancock Jaffe Enrolls and Successfully Implants Tenth VenoValve Patient

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
conix Member Profile
 
Followed By 174
Posts 27,722
Boards Moderated 4
Alias Born 10/10/05
160x600 placeholder
Securities Registration Statement (s-1) Edgar (US Regulatory) - 7/2/2020 5:38:22 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/24/2020 6:01:07 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 6/15/2020 5:26:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2020 5:16:05 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/11/2020 4:52:18 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/8/2020 5:02:26 PM
Report of Proposed Sale of Securities (144) Edgar (US Regulatory) - 6/8/2020 1:48:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 1:44:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2020 6:09:02 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/3/2020 6:06:09 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/15/2020 5:03:04 PM
Annual Statement of Changes in Beneficial Ownership (5) Edgar (US Regulatory) - 5/14/2020 9:47:20 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/14/2020 9:46:28 AM
Report of Proposed Sale of Securities (144) Edgar (US Regulatory) - 5/8/2020 6:07:29 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/28/2020 6:19:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/28/2020 6:05:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/20/2020 5:01:14 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/17/2020 6:01:30 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/10/2020 5:00:59 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 4/7/2020 4:49:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/3/2020 6:10:08 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/25/2020 5:01:01 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/18/2020 5:02:48 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 3/10/2020 9:23:25 AM
Report of Proposed Sale of Securities (144) Edgar (US Regulatory) - 3/5/2020 6:03:05 AM
conix   Friday, 11/15/19 01:10:16 PM
Re: Roland Rick Perry post# 51
Post # of 60 
Hancock Jaffe Enrolls and Successfully Implants Tenth VenoValve Patient

Initial Implantation Phase for First-in-Man Study Now Completed



IRVINE, California., November 15, 2019 – Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that it has enrolled and successfully implanted the 10th patient to complete the initial implantation phase of the first-in-man VenoValve study being conducted in Colombia. The surgery went very well with no early signs of adverse events.

Hancock Jaffe’s first-in-man study is the precursor to seeking permission from the U.S. Food and Drug Administration (“FDA”) to conduct the VenoValve U.S. pivotal trial. In consultation with the FDA, HJLI agreed to conduct a first-in-man study of between five and ten patients that suffer from chronic venous insufficiency (“CVI”). On October 24, 2019, HJLI released six month data on the first 5 patients that received VenoValves. The six month data showed significant improvements in all study endpoints, minimal safety issues, and dramatic improvement and healing of venous ulcers.



Dr. Marc. H. Glickman, Hancock Jaffe’s Senior Vice President and Chief Medical Officer, who was in Bogota for the VenoValve implantation procedure stated, “We have continued to refine and simplify the surgical procedure throughout the first-in-man study, so that we can now teach other vascular surgeons to replicate the success that we have had as we prepare for the U.S. pivotal trial.”



Next steps for the VenoValve include the continual monitoring of all VenoValve recipients, reengagement with the U.S. Food and Drug Administration (“FDA”), presentation of the six (6) month data to potential strategic partners, and a series of FDA mandated testing, all of which are in preparation for the filing of an IDE application with the FDA for the U.S. pivotal trial. HJLI will also develop a smaller version of the VenoValve.



Approximately 2.4 million people in the U.S. suffer from CVI due to reflux in the deep venous system, representing the potential for recurring revenue of hundreds of millions of dollars per year. Estimates indicate that direct medical costs from CVI in the U.S. exceed $30 Billion a year. There are currently no FDA approved devices or effective treatments for deep venous CVI.

Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist